Labor, Health And Human Services, Education, Agriculture, Rural Development, Energy And Water Development, Financial Services And General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, And Housing And Urban Development Appropriations Act, 2022
Mr. Speaker, I rise today in support of my amendment to H.R. 4502, the consolidated appropriations legislation that will fund, among other Federal agencies, the Department of Health and Human Services, including the National Institutes of…
Mr. Speaker, I rise today in support of my amendment to H.R. 4502, the consolidated appropriations legislation that will fund, among other Federal agencies, the Department of Health and Human Services, including the National Institutes of Health.
This bill represents a strong investment in our national health care infrastructure, workforce, and research and development enterprise--and I thank Chairwoman DeLauro for her strong leadership in ensuring that Congress invests in the health of the American people as we continue to recover from the COVID-19 pandemic. However, the health care challenges are more diverse than COVID-19 alone and warrant our careful attention and consideration. The historic investments in the National Institutes of Health, National Cancer Institute, and other health agencies are critical to addressing many of these health conditions and social issues.
I offered my amendment to this bill to address a critical gap in our fight to improve care for and save the lives of America's most vulnerable children--pediatric brain cancer patients. We have invested in intensive clinical and biological research for years, including through the National Cancer Institute, to investigate the origins of and therapeutic options for pediatric cancers, but the mortality of children with brain cancer remains high and is the leading cause of pediatric cancer deaths.
While brain tumors are rare in number among pediatric patients, the vulnerability of the patient population, combined with the array of tumor subtypes, makes investigating and treating this terrible condition a unique challenge for researchers. The National Cancer lnstitute's Childhood Cancer Data Initiative is one effort to undertake the difficult work of collecting phenotypic and genotypic data for pediatric cancer patients to inform the biologic and molecular underpinnings of these rare cancers.
I fully support this initiative--and my amendment would strengthen its current work by directing the Childhood Cancer Data Initiative to incorporate a key tool for researchers into its workflow--molecular tumor board data. Molecular tumor boards use information from each patient's tumor, including derived genotype and RNA and DNA profiling, and links research to the clinical characteristics of the child, to inform treatment decisions. These data sets are a rich source of real- world information that clinical scientists, treating physicians, and families will be able to use in real time to make critical decisions on care. Over time, they will improve our understanding of pediatric cancers' origins and functions and also assist in the development of new drugs, treatments, and potential cures.
Specifically, my amendment provides $2 million in further resources for the National Cancer Institute's Childhood Cancer Data Initiative, which should be sufficient resources to incorporate data from the 2000 most highly malignant brain tumor cases that occur in American children each year. The Initiative is well positioned to incorporate molecular tumor board data from diverse patients across the country, to work with academic centers that have the expertise to review the data and suggest treatment options, provide tumor board report information to patients and families, and to follow cases for clinical endpoints on a longitudinal basis.
Mr. Speaker, America's scientific and medical communities lead the world in groundbreaking, lifesaving research, and this bill rightly invests in furthering that national interest and strength. My amendment builds on this goal by centering research on some of the most vulnerable patients and some of the most unique and deadly health conditions that affect America's children. These tumors and cancers need innovative strategies to improve
care, quality of life, and survival. This research addresses the needs of pediatric brain cancer patients and their families to access precision-based therapeutics and medical experts. I urge my colleagues to support my amendment and the underlying bill to invest in the health of America's kids.